Rare disease patients face treatment dead-ends when biotech companies fail before therapies reach market

Patients with rare genetic disorders like Fabry disease have extremely limited treatment options, and when the biotech companies developing their only potential cures file for bankruptcy, those patients lose access to promising therapies. Current solutions fail because gene therapy development requires massive capital investment, and small biotech firms often collapse before completing clinical trials, leaving patients with no recourse and no alternative treatments available.